These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 30018074)

  • 1. Impact of immunopathology on the antituberculous activity of pyrazinamide.
    Blanc L; Sarathy JP; Alvarez Cabrera N; O'Brien P; Dias-Freedman I; Mina M; Sacchettini J; Savic RM; Gengenbacher M; Podell BK; Prideaux B; Ioerger T; Dick T; Dartois V
    J Exp Med; 2018 Aug; 215(8):1975-1986. PubMed ID: 30018074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological and Molecular Mechanisms Behind the Sterilizing Activity of Pyrazinamide.
    Gopal P; Grüber G; Dartois V; Dick T
    Trends Pharmacol Sci; 2019 Dec; 40(12):930-940. PubMed ID: 31704175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of host PARP1 contributes to the anti-inflammatory and antitubercular activity of pyrazinamide.
    Krug S; Gupta M; Kumar P; Feller L; Ihms EA; Kang BG; Srikrishna G; Dawson TM; Dawson VL; Bishai WR
    Nat Commun; 2023 Dec; 14(1):8161. PubMed ID: 38071218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis.
    Ahmad Z; Tyagi S; Minkowsk A; Almeida D; Nuermberger EL; Peck KM; Welch JT; Baughn AS; Jacobs WR; Grosset JH
    Indian J Med Res; 2012 Nov; 136(5):808-14. PubMed ID: 23287128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China.
    Pang Y; Zhu D; Zheng H; Shen J; Hu Y; Liu J; Zhao Y
    BMC Infect Dis; 2017 Nov; 17(1):711. PubMed ID: 29110640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular epidemiological study of pyrazinamide-resistance in clinical isolates of mycobacterium tuberculosis from South India.
    Muthaiah M; Jagadeesan S; Ayalusamy N; Sreenivasan M; Prabhu SS; Muthuraj U; Senthilkumar K; Veerappan S
    Int J Mol Sci; 2010 Jul; 11(7):2670-80. PubMed ID: 20717529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of pyrazinamide-monoresistant Mycobacterium tuberculosis in Quebec.
    Yee DP; Menzies D; Brassard P
    Int J Tuberc Lung Dis; 2012 May; 16(5):604-9. PubMed ID: 22409887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of pyrazinamide resistance on multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan.
    Kuhlin J; Smith C; Khaemraev A; Tigay Z; Parpieva N; Tillyashaykhov M; Achar J; Hajek J; Greig J; du Cros P; Moore D
    Int J Tuberc Lung Dis; 2018 May; 22(5):544-550. PubMed ID: 29663960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming the pitfalls of automatic interpretation of whole genome sequencing data by online tools for the prediction of pyrazinamide resistance in Mycobacterium tuberculosis.
    Iwamoto T; Murase Y; Yoshida S; Aono A; Kuroda M; Sekizuka T; Yamashita A; Kato K; Takii T; Arikawa K; Kato S; Mitarai S
    PLoS One; 2019; 14(2):e0212798. PubMed ID: 30817803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
    Ding Y; Zhu H; Fu L; Zhang W; Wang B; Guo S; Chen X; Wang N; Liu H; Lu Y
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0065822. PubMed ID: 35924925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrazinamide resistance, Mycobacterium tuberculosis lineage and treatment outcomes in San Francisco, California.
    Budzik JM; Jarlsberg LG; Higashi J; Grinsdale J; Hopewell PC; Kato-Maeda M; Nahid P
    PLoS One; 2014; 9(4):e95645. PubMed ID: 24759760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand.
    Jonmalung J; Prammananan T; Leechawengwongs M; Chaiprasert A
    BMC Microbiol; 2010 Aug; 10():223. PubMed ID: 20727143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global status of phenotypic pyrazinamide resistance in
    Wang Z; Tang Z; Heidari H; Molaeipour L; Ghanavati R; Kazemian H; Koohsar F; Kouhsari E
    J Chemother; 2023 Nov; 35(7):583-595. PubMed ID: 37211822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An explainable machine learning platform for pyrazinamide resistance prediction and genetic feature identification of Mycobacterium tuberculosis.
    Zhang A; Teng L; Alterovitz G
    J Am Med Inform Assoc; 2021 Mar; 28(3):533-540. PubMed ID: 33215194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the host environment on the antitubercular action of pyrazinamide.
    Lamont EA; Baughn AD
    EBioMedicine; 2019 Nov; 49():374-380. PubMed ID: 31669220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introducing molecular testing of pyrazinamide susceptibility improves multidrug-resistant tuberculosis treatment outcomes: a prospective cohort study.
    Sun F; Li Y; Chen Y; Guan W; Jiang X; Wang X; Ren P; Li J; Shi J; He G; Wu M; Tang P; Wang F; Sheng Y; Huang F; Zhou Z; Huang H; Hong L; Liu Q; Zhang Y; Zhang W
    Eur Respir J; 2019 Mar; 53(3):. PubMed ID: 30578402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proficiency of drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide: the Swedish experience.
    Hoffner S; Angeby K; Sturegård E; Jönsson B; Johansson A; Sellin M; Werngren J
    Int J Tuberc Lung Dis; 2013 Nov; 17(11):1486-90. PubMed ID: 24125455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prevalence and transmission of pyrazinamide-resistant
    Liu BB; Hu PL; Chen ZH; Yi SL; Zhang XP; Tan YH
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Jul; 45(7):677-685. PubMed ID: 35768376
    [No Abstract]   [Full Text] [Related]  

  • 19. Calcitriol enhances pyrazinamide treatment of murine tuberculosis.
    Zhang J; Guo M; Huang ZX; Bao R; Yu Q; Dai M; Wang X; Rao Y
    Chin Med J (Engl); 2019 Sep; 132(17):2089-2095. PubMed ID: 31425356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrazinamide resistance-conferring mutations in pncA and the transmission of multidrug resistant TB in Georgia.
    Sengstake S; Bergval IL; Schuitema AR; de Beer JL; Phelan J; de Zwaan R; Clark TG; van Soolingen D; Anthony RM
    BMC Infect Dis; 2017 Jul; 17(1):491. PubMed ID: 28697808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.